Table 1 Clinical characteristics at baseline of the melanoma samples included in the study.
Variable | Retrospective cohort, N = 108 (%) | Prospective cohort, N = 45 (%) |
|---|---|---|
Age | ||
≤60 | 54 (50) | 24 (53) |
>60 | 54 (50) | 21 (47) |
Gender | ||
Female | 38 (35) | 14 (31) |
Male | 70 (65) | 31 (69) |
Mutation status | ||
BRAF mutant | 81 (75) | 32 (71) |
NRAS mutant | 11 (10) | 4 (9) |
BRAF/NRAS WT | 16 (15) | 9 (20) |
Treatment | ||
ICI | ||
Pembrolizumab | 22 (20) | 6 (13) |
Ipilimumab/Nivolumab | 15 (14) | 15 (34) |
Ipilimumab | 11 (10) | |
Targeted therapies | ||
Vemurafenib | 3 (3) | 1 (2) |
Dabrafenib/Trametinib | 54 (50) | 16 (36) |
Vemurafenib/Cobimetinib | 2 (2) | 4 (9) |
Adjuvant | ||
Nivolumab | 1 (1) | 1 (2) |
Clinical trials | 2 (4) | |
No progressive disease | – | 29 (64) |
Progressive disease | 108 (100) | 16 (36) |
Response prior to PD | ||
Yes | 67 (62) | 16 (36) |
ctDNA not elevated at PD | 34 (31) | 7 (16) |
ctDNA elevated at PD | 33 (31) | 9 (20) |
ctDNA statistically elevated at PD | 20 (19) | 5 (11) |
No | 41 (38) | – |
AJCC stage/M classification at PD | N = 16 | |
M1a | 19 (18) | 5 (31) |
M1b | 5 (5) | 2 (13) |
M1c | 51 (47) | 4 (25) |
M1d | 33(30) | 5 (31) |
Brain-only metastasis at PD | ||
Yes | 9 (8) | 4 (25) |
No | 99 (92) | 12 (75) |
